Product Image

METOPROLOL SUCCINATE PROLONGED RELEASE 25 MG

RS 40 RS 36

(0 customer review)



In stock

Metoleco-25xl Tablet 15s is a highly versatile and widely used member of the beta-blocker class of medications. It is specifically a selective beta-1 receptor antagonist, meaning it primarily targets the beta-1 receptors found mainly in the heart, minimising effects on beta-2 receptors in the lungs at lower doses. This cardioselectivity is key to its safety profile, especially in patients with co-existing mild respiratory conditions. The mechanism of action centres on the competitive inhibition of the effects of sympathetic neurotransmitters (epinephrine and norepinephrine) at the cardiac beta-1 receptors. By blocking these receptors, Metoprolol significantly reduces the three major determinants of cardiac oxygen demand: Heart Rate (Chronotropy): Reduces the speed of electrical conduction and heart rate. Contractility (Inotropy): Decreases the force with which the heart muscle contracts. Blood Pressure: Lowers peripheral vascular resistance over time, reducing the pressure the heart must pump against. The Metoprolol Succinate formulation is crucial because it is an extended-release (ER) product. The succinate salt allows for a sophisticated drug delivery system that slowly releases the active drug over a whole 24-hour period. This pharmacokinetic stability avoids the rapid fluctuations in plasma concentration associated with immediate-release (IR) formulations like Metoprolol Tartrate. For patients, this translates into: Smoother Efficacy: Consistent blood pressure and heart rate control throughout the day and night. Improved Adherence: Simplifies dosing to a single, once-daily tablet. Reduced Side Effects: Minimises the risk of acute side effects that can occur with high drug peaks immediately after taking an IR dose. It is one of the few beta-blockers proven in large clinical trials (e.g., MERIT-HF) to reduce morbidity and mortality in patients with stable, symptomatic chronic heart failure, a core distinction from many other beta-blockers. The 47.5mg dose is a typical starting or low-to-moderate maintenance dose, often titrated up to 190mg depending on patient response and condition. .

Reviews (0)